#### 1 **A randomized controlled trial of postbiotic administration during antibiotic treatment**

#### 2 **increases microbiome diversity and enriches health associated taxa.**

- 3 Jonas Schluter<sup>1-4\*</sup>, Fanny Matheis<sup>1</sup>, Wataru Ebina<sup>1,3</sup>, William Jogia<sup>1,2</sup>, Alexis P. Sullivan<sup>1</sup>, Kelly
- 4 Gordon<sup>4</sup>, Elbert Fanega de la Cruz<sup>5</sup>, Mary E Victory-Hays<sup>5</sup>, Mary Joan Heinly<sup>5</sup>, Catherine S.
- 5 Diefenbach<sup>3</sup>, Jonathan U. Peled<sup>4,6,7</sup>, Kevin R. Foster<sup>4,8,9</sup>, Aubrey Levitt<sup>4</sup>, Eric McLaughlin<sup>4,6</sup>
- 6
- <sup>1</sup> 7 Institute for Systems Genetics, New York University Grossman School of Medicine, New York,
- 8 NY, USA
- 9<sup>2</sup> Department of Microbiology, New York University Grossman School of Medicine, New York,
- 10 NY, USA
- <sup>3</sup> Laura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine,
- 12 New York, NY, USA
- 13 <sup>4</sup> Postbiotics Plus Research, Houston, TX, USA
- <sup>5</sup> Patients Emergency Room & Hospital 10133 I-10, Baytown, TX, USA
- 15 <sup>6</sup> Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan
- 16 Kettering Cancer Center, New York, NY, USA
- 17 7 Weill Cornell Medical College, New York, NY, USA
- 18 8 Department of Biology, University of Oxford; Oxford, UK
- 19 <sup>9</sup> Department of Biochemistry, University of Oxford; Oxford, UK
- 20 **\*) correspondence: jonas.schluter@nyulangone.org**
- 21
- 22 Postbiotic administration during antibiotic treatment increases bacterial alpha diversity
- 23 Characteristic bacterial signatures are associated with postbiotic administration
- 24 Health-associated taxa are enriched and disease-associated taxa are reduced by postbiotic 25 treatment
- 26
- 27

#### **Author contributions**

- AL and EM conceived of the trial, with support by JS. AL, EM, oversaw and conducted the trial,
- with support by KG, EFC, MEVH, and MJH. JS conducted the analyses and wrote the
- manuscript with support by CSD, WE, FM, APS, and JUP. JS, FM, WE, WJ, KRF and JUP
- analyzed and interpreted the results. All authors read and commented on the manuscript.
- 

#### **Acknowledgements**

- JS reports funding from the National Institutes of Health (NIH) grants DP2 AI164318-01, and
- R01CA269617. FM is supported by a Helen Hay Whitney Fellowship. JUP reports funding from
- NHLBI NIH Award K08HL143189, the MSKCC Cancer Center Core Grant NCI P30 CA008748.
- We would like to thank Kate Markey for comments and discussion of the manuscript.
- 

#### **Conflict of Interest Disclosure**

- AL is CEO of Postbiotics Plus Research. AL and JS are co-founders of Postbiotics Plus Research.
- AL, JS, EL, KRF, JUP hold equity in Postbiotics Plus Research. JUP reports research funding,
- intellectual property fees, and travel reimbursement from Seres Therapeutics, and consulting fees
- from DaVolterra, CSL Behring, and from MaaT Pharma. JUP has filed intellectual property
- applications related to the microbiome (reference numbers #62/843,849, #62/977,908, and
- #15/756,845). Memorial Sloan Kettering Cancer Center (MSK) has financial interests relative to
- Seres Therapeutics. AL and JS have filed intellectual property applications related to the
- microbiome (reference numbers #63/299,607). JUP and KRF serve on an Advisory board of
- Postbiotics Plus Research. JS serves on an Advisory board and holds equity of Jona Health.

#### **Abstract**

 Antibiotic-induced microbiome injury, defined as a reduction of ecological diversity and obligate anaerobe taxa, is associated with negative health outcomes in hospitalized patients, and healthy individuals who received antibiotics in the past are at higher risk for autoimmune diseases. No interventions are currently available that effectively target the microbial ecosystem in the gut to prevent this negative collateral damage of antibiotics. Here, we present the results from a single- center, randomized placebo-controlled trial involving 32 patients who received an oral, fermentation-derived postbiotic alongside oral antibiotic therapy for gastrointestinal (GI)- unrelated infections. Postbiotics comprise complex mixtures of metabolites produced by bacteria during fermentation and other processes, which can mediate microbial ecology. Bacterial ecosystem alpha diversity, quantified by the inverse Simpson index, during the end of the antibiotic course was significantly higher (+40%) across the 16 postbiotic-treated patients compared with the 16 patients who received a placebo, and the postbiotic was well-tolerated. Secondary analyses of 157 stool samples collected longitudinally revealed that the increased diversity was driven by enrichment in health-associated microbial genera: obligate anaerobe Firmicutes, in particular taxa belonging to the Lachnospiraceae family, were higher in treated patients; conversely, *Escherichia/Shigella* abundances, which comprise pathobionts and antimicrobial-resistant strains, were reduced in postbiotic-treated patients at the end of their antibiotic course and up to 10 days later. Taken together, these results indicate that postbiotic co- administration during antibiotic therapy could support a health-associated gut microbiome community and may reduce antibiotic-induced microbiome injury.

#### 72 **Introduction / Background**

73 Antibiotic therapy is the most effective treatment to fight bacterial infections and indispensable  $\frac{1}{2}$  in modern medicine; it can cure mild disease and save lives in severe cases of bacteremia<sup>1</sup>, organ 75 invasion and sepsis<sup>2</sup>. Recently, however, evidence has accumulated that oral antibiotic treatment 76 may collaterally injure the human microbiome<sup>3–11</sup>. Antibiotics may interfere with commensal 77 bacterial growth, or can kill health-associated bacterial populations  $3,9$ , a phenomenon that may 78 have been vastly underestimated<sup>3</sup>. Such disruption of the commensal microbial ecosystem can 79 persist for months following antibiotic exposure<sup>7</sup> and is seen in otherwise healthy individuals<sup>12</sup> 80 as well as severely immunocompromised, hospitalized patients who, in some instances, lose 81 most of the normally resident bacteria<sup>8–11</sup>. Clearance of the normal flora can enable persistent 82 colonization by pathogens, e.g., *Clostridioides difficile*, and cause recurrent, difficult-to-cure, 83 infections<sup>13,14</sup>.

84 Antibiotic-induced interference with bacterial reproduction and killing of gut bacterial 85 populations lead to shifts in the gut microbiome ecosystem that can be characterized by a decline 86 in alpha diversity<sup>9,10,15</sup>. Alpha diversity metrics are summary measures quantifying the ecological 87 composition of a microbiome sample; they may capture the number of taxonomic groups (e.g. 88 more taxa increase diversity) and their abundance distributions (e.g. more evenly distributed 89  $\pm$  taxon abundances increase diversity)<sup>16</sup>. Therefore, they have been used to quantify microbiome 90 injury at the ecosystem level<sup>17</sup>. Notably, antibiotic use and loss of bacterial microbiome alpha 91 diversity have been associated with health risks, including higher mortality in hematopoietic 92 stem cell transplantation<sup>18,19</sup>, translocation of microorganisms from the gut into the bloodstream 93 (often resulting in bacteremia and sepsis) in immunocompromised patient populations<sup>10,11,15,20,21</sup>, 94 increased risk for inflammatory bowel disease<sup>22</sup> and severity of autoimmune and allergic 95  $\frac{\text{disease}^{23-27}}{\text{disease}^{23-27}}$ . Furthermore, loss of bacterial diversity can affect cross-kingdom interactions: 96 depletion of bacterial competitors may allow for fungal species to expand<sup>28</sup>, and fungal 97 expansions were associated with increased risk of fungal bloodstream infections in cancer 98 patients<sup>15</sup> as well as fungal urogenital infections in otherwise healthy women<sup>29</sup>. Recently, 99 antibiotic exposure has been associated with worse response to cancer immunotherapies  $30-34$ , and 100 direct links between perturbation of the microbiome and human immune system modulation are 101 emerging  $35-37$ .

 A diverse microbiome, predominantly populated by obligate anaerobe taxa, is thus associated with good health. As a result, means to restore the microbiome following antibiotic exposure are much sought after. Autologous fecal microbiota transplantation (auto-FMT) can recover antibiotic-depleted bacteria using fecal materials harvested and stored prior to 106 treatment<sup>38</sup>. Heterologous FMTs with material from healthy donors (allo-FMT) have shown 107 promising results in improving inflammatory bowel disease<sup>39</sup>, response to immune therapy<sup>40</sup>, and 108 successfully reduced *C. difficile* abundances and recurrence<sup>41,42</sup>. FMTs, however, come with risks<sup>43</sup>: antimicrobial-resistant strains are prevalent in the microbiome<sup>11</sup> and can sometimes cause 110 life-threatening complications during  $FMT<sup>44</sup>$ . Furthermore, matching donor to recipients for 111 optimal engraftment remains an unsolved challenge<sup>45</sup>. Nevertheless, recently, the U.S. Food and Drug Administration has approved two FMT-based therapies: a rectally administered single dose of prepared stool from healthy donors and a fecal microbiota-based oral treatment, both to 114 prevent the recurrence of *C. difficile* infection<sup>46,47</sup>. In addition to large community transfers via FMT, administration of selected live microbial species, termed probiotics, have been established, 116 albeit with conflicting data on efficacy<sup>48,49</sup>, and variable recipient colonization<sup>50,51</sup>. Whilst probiotics are generally assumed to be safe, their use has been associated with adverse 118 outcomes<sup>48</sup>, such as bacteremia<sup>52</sup>, fungemia<sup>53</sup>, and bowel ischemia<sup>49</sup> especially in immunocompromised and critically ill patients. Facilitation of probiotic colonization following antibiotic-induced depletion of recipient commensals can also lead to persistent dysbiosis and delay recovery of the pretreatment microbiome<sup>54</sup>. These shortcomings of probiotics highlight the potential benefit of modulating resident commensal microbial ecology without the addition of new microbial strains and species towards safe and robust microbe-targeted therapies. Aside from live therapeutics, one potential alternative is the use of prebiotics. These are substances intended to provide nutrients to specific, desired microbial populations, and have recently been 126 shown to have some effects on microbiome communities<sup>37</sup>. Surprisingly, however, a beneficial, anti-inflammatory effect was observed resulting from increased consumption of fermented foods<sup>37</sup>. Thus, products of fermentation may offer a novel therapeutic avenue to manipulate the microbiome.

 As such, an emerging alternative to live therapeutics, which we explore here, is the use of postbiotics. Postbiotics is an umbrella term that comprises complex mixtures of metabolites

 produced by bacteria for example during fermentation, as well as cell wall components and other 133 dead cell components (as well as some potentially viable cells<sup>55</sup>).

 Emerging pre-clinical and clinical studies indicate health-beneficial effects of 135 postbiotics<sup>37,56,57</sup>. Thus, postbiotics may offer a safe novel therapeutic avenue to target the microbiome. In particular, we hypothesize that reduction of antibiotic-induced microbiome damage could prevent antibiotic-induced impairment of novel immunotherapies and health 138 sequalae<sup>30,58</sup>. However, it is not yet known if postbiotics can reduce microbiome diversity loss during antibiotic treatment. Here, we describe the results of a single-center randomized controlled trial to assess the ability of a fermentation-derived postbiotic to prevent antibiotic- induced injury to the commensal microbiome in patients receiving oral antibiotics. Following a course of antibiotics, we collected stool samples at five timepoints and profiled the composition of bacterial populations. Our data indicate that treatment with a postbiotic during a course of oral antibiotics supports gut microbial ecosystem stability and health-associated taxa.

#### **Results**

#### **Overview of study design and intervention**

148 A single-center, randomized placebo-controlled trial of postbiotic treatment  $(T, n=16)$  versus 149 placebo  $(C, n=16)$  was conducted to measure bacterial alpha diversity as a primary endpoint at the end and directly after finishing a course of oral antibiotics. The goal was to determine feasibility, safety, and a preliminary efficacy assessment of the procedure for prevention of medication-induced injury of the gut microbiota (Study title: Randomized controlled trial of PBP-GP-22 to affect microbiome composition; https://www.isrctn.com; trial registration ISRCTN30327931). Otherwise healthy ambulatory adult patients (**Table 1**) presenting to a single clinical site in Houston, Texas, between 05 and 06/2018 for non-gastrointestinal infections were recruited. After giving informed consent, patients were provided with take-home stool sample collection kits, a supply of a commercially available probiotic, and a supply of the placebo (control, C) or postbiotic (treatment, T) to be taken during and ten days beyond the antibiotic course (administered antibiotics are listed in **Table S1**) along with the commercial probiotic and their standard-therapy antibiotic (**Figure 1, S1**, CONSORT report<sup>59</sup>). We chose to include the probiotic background, which included six strains of *Lactobacillus* and *Bifidobacterium*, because it was the standard recommendation by the participating physicians when administering

163 antibiotics. Moreover, by including an existing treatment in our study, our design represented a 164 relatively stringent test of the ability of a postbiotic to further improve outcomes. A total of 157 165 stool samples were collected longitudinally, for up to five timepoints (S1-S5) relative to the end

166 of a full course of prescribed antibiotics per patient (**Figure 1A**).

167 It was hypothesized that microbiome injury would be maximal at the end of a completed 168 course of antibiotics. Therefore, the primary endpoint was set as bacterial alpha diversity,

- 169 measured by the inverse Simpson index on three timepoints at the end of the antibiotic course: on
- 170 the day prior to finishing the antibiotic treatment (S1), directly after completing the antibiotic (S2)
- 171 and one day thereafter (S3). Among patients who entered the study, stool sampling rates were

172 high, with only a single sample from S3 missing in the final analysis set (FAS, target participant

173 number: 25, FAS: 32, **Figure 1B**). Patients were given a phone number to call to report any side

174 effects, and were contacted via text messages prior to fecal sample collection; there were no

- 175 grade 3 or higher side effects reported (**Table S2**).
- 176

177 **Table 1:** Patient characteristics and indications by treatment arm, with statistical tests for *p* value 178 calculations indicated.

Characteristic		Control	<b>Treatment</b>	$p$ value
Age		39, [20,60]	45, [20, 64]	$0.95$ (t-test)
<b>Sex</b>	Female	10	8	$0.72$ (Chi <sub>2</sub> )
	Male	6	8	
Disease				
	<b>Sinusitis</b>	5	3	
	Cellulitis	$\mathcal{D}_{\mathcal{L}}$		
	Kidney infection/UTI		0	
	Abscess		0	
	Ear infection	2	0	
	Cyst		0	
	Pharyngitis/Strep		6	
	<b>Bronchitis</b>		2	
	Laceration	$_{0}$		
	Toothache	$\Omega$		
	Other	2	$\overline{2}$	

## **Bacterial alpha diversity at the end of an antibiotic course is high in patients receiving the**

#### **postbiotic**

 Microbiome profiling by amplification and sequencing of the V4 region of the 16S rRNA gene was performed on DNA collected from 157 samples. Bacterial alpha diversity measured at the end of the antibiotic treatment (S2) was significantly higher in postbiotic-treated patients compared with placebo recipients for different alpha diversity metrics (**Figure 1C**, Shannon: +24%, p=0.046; Simpson: +19%, p=0.048; inverse Simpson: +43%, p=0.056, t-test). Time series 187 analysis<sup>38</sup> of longitudinally collected samples (**Figure S2**) showed that postbiotic-treated patients had significantly higher alpha diversity during the end phase of their antibiotic treatment (**Figure 1D**, p=0.037, linear mixed effects model). Together, these results indicate that addition of this postbiotic to an orally-administered antibiotic course is clinically feasible, well-tolerated, and significantly increased gut microbial alpha-diversity.

#### **Postbiotic treatment is associated with characteristic bacterial signatures**

 We next sought to analyze differences between microbial ecosystems in treated vs control patients at a higher resolution than resolved by alpha diversity metrics. For this, we first visualized the individual patients' compositional time courses by plotting the relative abundances of the most abundant bacterial families (**Figure 2A**), which indicated compositional variation across patients and changes over time in several individuals. To analyze compositional variability, we next performed a principal coordinate analysis (PCoA) on sample-by-sample Bray-Curtis distances calculated on operational taxonomic units' (OTUs) relative abundances (**Figure 2B-E**). Samples from patients of either sex localized across the projected bacterial compositions (**Figure 2B**). In most samples, obligate anaerobe Bacteroidetes taxa represented the most abundant bacterial families (**Figure 2C**), whereas samples from both experimental arms contained only low relative abundances of the genera corresponding to the probiotics taken by all patients (median relative genus abundance: *Bifidobacterium* [C: 3.9e-4, T:4.3e-4], *Lactobacillus* [C: 1e-4, T: 0.9e-4]; **Figure S3**). Consecutive samples from the same patient tended to localize near one another, with significantly lower intra- than inter-patient variability during the transition from antibiotics into the post-antibiotic period (**Figure 2D**), even though the observed microbiome dynamics in several patients spanned wide regions of the compositional space. While samples from treated and control patients localized across the PCoA space, a statistical

- analysis indicated that the samples from treated patients varied consistently in their composition
- from those observed in control patient samples (**Figure 2E**), which suggested characteristic gut
- bacterial communities in treated patients.
- 

# **Postbiotic treatment is associated with an enrichment in health- and a reduction in disease-**

## **associated taxa**

 To analyze which taxa were consistently higher in treated patients or lower alongside the reduced diversity in control patients, we compared the relative abundance profiles between the two patient groups directly after finishing the antibiotic course (S2), and over time (S1-S3). To account for the compositional nature of 16S relative abundance data, we calculated the centered- log ratio (CLR) transformation of relative taxon abundances across all samples. To reduce sparsity of the OTU-level data, we aggregated relative abundances at the phylum, family or genus levels prior to CLR transformation.

 Statistical comparison of the CLR-transformed phylum relative abundances directly after finishing the antibiotic course (S2) revealed a significantly higher abundance of Firmicutes among treated patients (**Figure 3A**, p-value=0.002, q-value<0.05, 0.1 FDR). At higher taxonomic resolutions, we analyzed the 10 most abundant bacterial families and 20 most abundant genera after CLR-transformation: Lachnospiraceae and Bacteroidaceae (family-level analysis), and *Roseburia*, *Bacteroides*, and *Ruminiclostridium* 5 (genus-level analysis) were enriched in treated patients at S2 (**Figure 3B, C**). However, the observed taxon enrichments, while significant in univariate analyses, did not remain significant after correcting for multiple hypotheses, with the exception of the observed enrichment of Lachnospiraceae in treated patients 233 (univariate p-value=0.004,  $q<0.05$ , 0.1 FDR), which remained significant. We next analyzed CLR-transformed genus abundances in samples S1 to S3. Using a more stringent false discovery rate (0.05 FDR) as well as a minimal effect size cutoff (0.5),

revealed several genera significantly enriched in treated patients, including *Anaerostipes*,

- *Eubacterium coprostanoligenes* group, *Fusicantenibacter*, and *Roseburia*, and significantly
- reduced genera in treated patients, including *Fusobacterium* and *Escherichia/Shigella* (**Figure**
- **3D**, **S4**). We tested the 13 differentially abundant genera in a mixed effects model (**Figure 3E**),
- which confirmed the associations found in the univariate pooled analysis screen (**Figure 3D**).
- Furthermore, consistent with these results, we found similar associations when performing

 multivariate analyses using regularized regression approaches (**Figure S5**), which confirmed a trend towards enrichment of commensal obligate anaerobe genera among treated patients. We also compared the abundances of anaerobe taxa discussed as immunomodulatory in the context 245 of cancer therapies<sup>31,32,35</sup>, and found higher abundances of Lachnospiraceae, which comprise *Faecalibacterium*, Ruminococcaceae, which comprise *Ruminococcus*, and Verrucomicrobiaceae, which comprise *Akkermansia*, in treated patients (**Figure S6**). Interestingly, this enrichment of health-associated anaerobe taxa and concurrent lower levels of facultative anaerobe, pathobiont- comprising taxa in treated patients appeared to persist beyond the immediate end of the antibiotic exposure (**Figure S7**), even though alpha diversity in control patients had already approached similar levels to treated patients ten days after the antibiotic course ended (**Figure S8**). In particular, facultative-anaerobe gamma-proteobacteria of the *Escherichia/Shigella* genus were reduced in treated patients even 10 days after finishing their antibiotic course (**Figure S7B**). Taken together, these results support an enrichment of a health-associated microbial community in patients treated with a postbiotic during their antibiotic course.

#### **Discussion**

 We here presented results from a single center randomized placebo-controlled trial to assess the protective effect of a postbiotic adjuvant on microbiome diversity during antibiotic therapy. Collateral injury to the resident gut microbiota caused by antibiotics has been described as a loss 261 of bacterial ecosystem diversity<sup>18</sup>, loss of commensal microbial taxa<sup>9,15</sup>, and increase of 262 pathobionts, which can comprise antibiotic-resistant species<sup>11</sup>. The enrolled patients were ambulatory and treated with oral antibiotics for non-gastrointestinal infections. Thus, the patient cohort studied here were at a lower risk for microbiome injury-induced complications than for 265 example blood cancer patients<sup>11,15,18</sup>. Among those higher-risk patients, overall survival is 266 statistically associated with antibiotic induced loss of diversity<sup>18</sup>, and response to chimeric 267 antigen receptor T cell therapy is negatively associated with antibiotic exposure  $30,34,58$ . In hospitalized COVID-19 patients, another high-risk patient group, a combination of antibiotics 269 and viral infection were found to predispose patients to gut born bacteremia<sup>10</sup>. Nevertheless, even in otherwise healthy individuals such as were studied here, post-antibiotic complications 271 such as diarrhoea<sup>60</sup>, post-antibiotic *Clostridioides difficile* infection<sup>61</sup>, or vaginal candidiasis<sup>62</sup> are common, and selection for antimicrobial resistant strains (AMR) in the gut microbiome may

 pose a potential health risk during future therapies. Therefore, reducing the negative collateral impact of antibiotics on the microbiome constitutes a critical unmet need.

 Our results indicate that microbiome injury is lower when co-administering an oral postbiotic alongside the oral antibiotic: bacterial alpha diversity was significantly higher at the end of an antibiotic course in patients who received the postbiotic instead of the placebo, and this increased diversity was driven by commensal taxa. Health-associated obligate anaerobe organisms were higher in treated patients: *Fusicantenibacter*, which is depleted in rheumatoid 280 arthritis patients<sup>63</sup>, short-chain fatty acid-producing *Roseburia*, one of the most abundant genera 281 in the healthy gut microbiome<sup>64</sup>, the butyrogenic *Anaerostipes* genus, which comprises lactateconsuming species65 , and the *Eubacterium coprostanoligenes* group, which has been 283 hypothesized to be involved in beneficial fat metabolism by reducing cholesterol<sup>66</sup>. Conversely, *Escherichia/Shigella*, a genus of gram negative facultative anaerobe species that comprise multiple antibiotic-resistant strains and pathobionts which can cause secondary bacteremia when 286 translocating across a weakened gut barrier<sup>10,11</sup>, were significantly lower in treated than in control patients. Interesting, we also observed that *Fusobacterium*, an obligate anaerobe taxon, was significantly lower in treated patients. Its predominant species, *F. nucleatum*, is commonly found in the oral microbiome and associated with the development of colorectal cancer when 290 abundant in the gut<sup>67,68</sup>. It is plausible that the higher diversity of commensal gut bacteria in treated patients improved colonization resistance and reduced gut colonization of *F. nucleatum* when swallowed. Furthermore, the higher diversity of commensal organisms may have suppressed the opportunistic expansion of *Escherichia/Shigella* observed in control patients via 294 competitive exclusion<sup>11,69–71</sup>.

 Limitations of the study include that both treatment arms received a commercial probiotic; however, low abundances of the taxa from the probiotics in both treatment arms indicated that this had no influence on the diversity differences observed between treatment arms. Nevertheless, future studies are warranted to validate the efficacy of the oral postbiotic outside of the context of concurrent probiotic administration. Furthermore, due to the enrollment at an urgent care clinic where patients were instructed to start their treatment immediately, no baseline stool sample prior to antibiotics was collected. However, we speculate that the impact of antibiotics on the microbiome are maximal at the end of an antibiotic course, and that thus the increase in diversity observed among treated patients could reflect protection of the commensal microbiome.

 This is a plausible scenario because of the enrichment of commensal taxa in the microbiome of patients treated with the postbiotic, which did not include these taxa. The study results, while significant and of considerable magnitude, are based on a small cohort and the direct impact on patients' health was not assessed in this trial, which focused on microbiome diversity as a primary outcome. Additional studies are now warranted to validate the herein described beneficial impact of postbiotic treatment on the microbiome and assess if the stabilization of the microbiome translates into a patient health benefit.

 Recently, consumption of fermented plant-based foods were described to have a 312 beneficial effect on the microbiome and immune system<sup>37</sup>. The postbiotic under investigation is a complex biologic product derived from the fermentation of medicinal plants by generally regarded as safe (GRAS) bacterial species. Unlike in fermented foods, manufacturing of 315 postbiotics generally includes a dedicated inactivation step that reduces live cell counts<sup>55</sup>, and therefore, they are assumed to have a generally favorable safety profile over live therapeutic based approaches. For the manufacturing of the postbiotic used in this trial, a fermentation process by specific species of *Lactobacillus* and *Bifidobacterium* was used, which represent 319 major taxa commonly present during the assembly of the infant microbiome<sup>72</sup>. While the mechanism of action of the observed protection of gut microbiome diversity is not fully understood, we hypothesize that bacterial metabolites of these species, their products of secondary metabolism and signaling molecules may support or elicit competitive responses within resident members of the commensal adult microbiome, which have evolved to ecologically succeed early colonizers of the gut microbiome<sup>73</sup>, increasing their resilience to 325 external perturbations<sup>74</sup>.

 In conclusion, here we have presented evidence that co-administering a fermentation derived postbiotic can increase gut microbiome diversity during antibiotic treatments. The increased diversity was associated with higher abundances of health-associated bacterial taxa, while genera comprising pathobionts were lower among postbiotic treated patients.

#### **Methods**

#### *Human subjects*

 **Table 1** reports metadata, including age and sex, corresponding to the 32 healthy adult subjects enrolled in a single site double-blind randomized controlled study (trial registration ID: ISRCTN30327931). This study was reviewed and approved by New England Institutional Review Board, an independent IRB located in Needham, MA. All subjects were provided with an explanation of the study and gave informed consent in writing prior to the start of their participation in the study.

#### *Human subject study methods*

 Fifty-one ambulatory adult subjects were initially evaluated for eligibility (see inclusion and exclusion criteria used to evaluate subject suitability listed below), one was not eligible. Fifty of the subjects were then enrolled in a single site double-blind interventional study with a randomized-controlled design to test the hypothesis that patients receiving an oral postbiotic would present with higher bacterial alpha diversity, measured by the inverse Simpson index, during three time points at the end of an antibiotic course than patients receiving a placebo control. Analyzed timepoints were: the final day of antibiotics, the first day after completing the antibiotics course, and the second day after completing the antibiotics course. Analysis was performed by time series analysis that accounts for repeated measurements and uses time as 349 categorical predictors, as done before<sup>38,75</sup>. This study was reviewed and approved by New England Institutional Review Board, an independent IRB located in Needham, MA. Eligibility for enrollment was determined by the following inclusion and exclusion criteria:

Inclusion criteria:

- 354 Otherwise healthy adults with a body mass index (BMI)  $(18-28 \text{ kg/m}^2)$
- 

355 • Patients are prescribed a course of antibiotics with a duration of at least 5 days

• Patients have not had another course of antibiotics in the past 6 months

• Patients are willing to cease taking any other supplements

Exclusion criteria:

 • patients suffering from gut related illness (regular and severe constipation, diarrhea, inflammatory bowel disorder or inflammatory bowel disease).

- patients who usually experience severe diarrhea (e.g. for more than 3 days) following antibiotic treatment.
- patients who have a compromised immune system, are taking any immune modulators or have an autoimmune disorder.
- patients who are diabetic or take any blood pressure medication.
- patients who have any known allergies to the probiotics, or the herbs and bacteria used in the postbiotic formula.
- patients who are pregnant or nursing.
- 

 The double-blind randomization scheme for this study was as follows. Patients were given an unmarked box (the study kit) containing stool sample materials, and either control or treatment materials neither of which were marked. To blind study coordinators, boxes had been shuffled after assembly of all study kits, prior to the study. Kits contained barcodes that allowed identification of participants' treatment arm after the participant handed over their samples. One of the subjects evaluated for participation was ineligible due to not meeting the inclusion criteria. Fifty subjects received the study kits. Seventeen subjects withdrew consent during follow-up; six and twelve subjects from the control and the treatment arm, respectively, without explanation. One patient from the treatment arm was removed from the study due to a second antibiotic prescription which was not declared during enrolment.

 Treatment regimens were as follows. In their study kit, the control arm received a commercially available probiotic in unmarked capsules and a resistant starch placebo in an unmarked capsule; the treatment arm received the same commercially available probiotic in unmarked capsules and the fermentation-derived postbiotic in unmarked capsules. Subjects were instructed to take one capsule of each every day during their antibiotic course and for ten days after finishing the antibiotic course.

 Patients were given a phone number to call to report any side effects; no such phone calls were received. Prior to the collection of each stool sample, study coordinators were checking in with patients via text message to remind them of the sample collection and ask for side effects, collectively presented in **Table 2**. Patients were contacted on study days 1,2,3,4 and 10, and there were no grade 3 or higher side effects reported.

#### 392 *Eligibility criteria, ethical approval, and consent to participate*

- 393 This study protocol was approved by the institutional review board (IRB) number: 120180088, 394 trial registration ID: ISRCTN30327931. Otherwise healthy ambulatory adult patients (**Table 1**) 395 presenting to a clinic in Houston, Texas, between 05 and 06/2018 for non-gastrointestinal 396 infections were recruited. Participants were recruited by physicians. Onsite nurses, trained in 397 human subject research, reviewed the consent form with the potential participants and answered 398 any questions about the study and its potential risks. Informed consent was obtained from all 399 participants. Participants were compensated with a \$15 Amazon gift card per sample collected at 400 the end of the study. If a participant did not complete the study, they were not penalized and 401 rewarded for the samples they collected.
- 402

#### 403 *Sample collection*

 After informed consent was obtained, participants were provided with 5 Diversigen OmniGene Gut kits for stool collection at home, a kit which stabilized samples at room temperature for up to 60 days. Patient were handed a work sheet listing their expected samples, recorded the date of sample collection, and shipped all samples in one batch. Samples were received and processed by a specialized contract research organization, Diversigen, (Houston, Texas).

409

#### 410 *Postbiotic composition*



#### *DNA extraction and bacterial 16S rRNA gene sequencing*

- DNA from human samples was extracted with PowerSoil Pro (Qiagen) on the QiaCube HT
- (Qiagen), using Powerbead Pro (Qiagen) plates with 0.5mm and 0.1mm ceramic beads. All PCR
- products were analyzed with the Agilent TapeStation for quality control and then pooled
- equimolar and sequenced directly in the Illumina MiSeq platform using the 2x250 bp protocol.
- Human samples were prepared with a protocol derived from 44, using KAPA HiFi Polymerase
- to amplify the V4 region of the 16S rRNA gene. Libraries were sequenced on an Illumina MiSeq
- using paired-end 2x250 reads and the MiSeq Reagent Kitv2. Sample processing and sequencing were performed by Diversigen.
- 

## *Bioinformatic processing and taxonomic assignment*

OTU tables were generated by Diversigen bioinformatics pipelines (detailed bioinformatic tools

and settings in **Supplementary Methods**). Briefly, Useach v7.0 was used to process raw

sequencing reads, and taxonomy was assigned via the Silva database v128.

#### *Statistical analyses*

 Unless otherwise stated, statistical analyses were performed with Python 3, version 3.10.4 and R, version 4.2.

 We calculated the inverse Simpson (IVS) index from relative ASV abundances (p) with 430 N ASVs in a given sample,  $IVS = \frac{1}{\sum_{i=1}^{N} p_i^2}$ . Regression analyses were conducted using the statsmodels package for the Python programming language, using the functions *ols* and *mixedlm*  for ordinary least squares and mixed effects modeling, respectively. Relevant code of primary analyses and corresponding data tables are available in the supplementary materials.

 To account for compositionality of the relative abundance data, we performed a centered log-ratio (CLR) transformations at different taxonomic aggregation levels, i.e. separate CLR for genus, family, and phylum abundances. While this does not remove compositionality related data analysis challenges, CLR transformations are increasingly used to reduce negative covariance biases in microbiome data. Regression models were implemented using the statsmodels (using 439 functions *ols* and *mixedlm*<sup> $76$ </sup> and penalized multiple variate regression models using the sklearn 440 packages (using the function *LogisticRegression*)<sup>77</sup> for the Python programming language, and 441 using the  $nIme^{78}$  and  $vegan^{79}$  library in R.

- *p* values were adjusted as appropriate. A *p*-value <0.05 was considered significant after adjustment for multiple comparisons where appropriate. Unless otherwise stated, significance 444 values are noted as follows: \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .
- Figure 1: Significance of differences in IVS were calculated using a mixed effects model 446 for repeated measures with time treated as a categorical variable  $38,75$ ; significance between arms at individual timepoints was determined using two-sided t-tests.
- Figure 2: Differences in sample-by-sample distances were calculated with the adonis2 function from the vegan library for the R programming language.

 Figure 3: Single time points were analyzed with univariate linear models using the *ols* function of the statsmodels package, multiple hypothesis correction was performed with the Benjamin/Hochberg procedure using the fdrcorrection function of the statsmodels.stats.multitest library for the Python programming language. The multivariate analysis of significant hits from the univariate screen was performed with the LogisticRegressionCV class from the scikit-learn package for the Python programming language. 

#### *Data availability*

Data, statistical test results, and relevant code to reproduce main analyses are available as

supplementary materials. The 16S rRNA gene sequencing results are available as supplementary

data files (**Table S3**). Raw sequencing reads are available on the sequencing read archive,

submission SUB13922145.

#### **Figures**



 

#### **Figure 1: Postbiotics significantly increased bacterial alpha diversity at the end of an**

**antibiotic course. A)** Sample collection protocol and study design; primary endpoint of the trial

was alpha-diversity (inverse Simpson index) during the end of the antibiotic course (S1-S3),

additional endpoints were alpha-diversity (inverse Simpson) at later time points (S4, S5). **B)**

- Enrolment and sample collection efficiency in percent of planned vs obtained; Full Analysis Set,
- (FAS): 100%=16 samples per arm; cohort report in **Figure S1**. **C)** Alpha diversity directly after
- finishing the antibiotic course (S2, p-values from two-sided t-tests). **D)** Inverse Simpson alpha
- diversity across timepoints S1-S3 was significantly higher in treated (purple) than control (grey)
- 473 patients, see also **Figure S2**; p-value from linear mixed effects model<sup>38</sup>.
- 
- 
- 
- 







 **Figure 3: Health-associated taxa are enriched in postbiotics treated patients. A-C)** Volcano plots of association coefficient effect sizes between CLR-transformed taxon abundances and treatment arm; 493 control (left), treatment (right) in samples collected at the end of an antibiotic course (S2). Negative  $log_{10}$ - transformed p-values of association coefficients from 10 most abundant phyla (**A**), families (**B**), and 20 most abundant genera (**C**); significant associations in color (light color: univariate p-value<0.05, full color: q-value<0.05, 0.1 FDR, Benjamin/Hochberg method). **D)** Volcano plot of associations between CLR-transformed relative genus abundances with treatment or control in samples S1-S3 (100 most abundant genera analyzed). **E**) Significant genera from D re-analyzed with a mixed effects model using random intercepts per patient to account for multiple samples per patient; colored bars indicate significant association coefficients (red: higher in control, blue: higher in treatment arm) after multiple hypothesis 501 correction via the Benjamin/Hochberg method (FDR: 0.1, q<0.05).

## 502 **Supplementary Material**

503

#### 504 **Table S1:** Antibiotic exposures by treatment arm

505



## 506

507

#### 508 **Table S2: Reported adverse events**

509



510

#### 511 **Table S3: Data and statistical model output.**

512 Supplementary file "Table S3 Data and Statistics.xlsx"

## 513 *Supplementary Figures*

514



515

516 **Figure S1: CONSORT Report chart**.



 

**Figure S2: Higher alpha diversity observed across individual patients during primary** 

**endpoints (S1-S3)**. Inverse Simpson alpha diversity in 32 patients (Control: PC, Treated: PT) at

the end of an antibiotic course across samples S1, S2, S3; patients sorted by trial arm and

average diversity in descending order from top left to bottom right. Dashed lines indicate control

- (grey) and treated (red) patient averages.
- 
- 



## 

Sample Point

 **Figure S3: Relative abundances of probiotic genera**. Relative genus abundances shown for samples from control (grey) and treated (purple) patients; differences were non-significant at each time point between treatment arms (Wilcoxon rank sum tests).











542 **confirm univariate results.** Coefficient estimates from L1-penalized logistic regressions on

543 performed on CLR-transformed genus relative abundances in Sample S2 (**A**), or samples S1-S3

544 (**B**), at different regularization strengths up until all coefficients were set to zero (C: inverse

545 regularization strength).



- 548 **Figure S6: Relative abundance of bacterial families and genera**, sorted by average abundance.
- 549 Log-10 transformed relative family abundances in sample S2 (**A**) and genus (**B**) abundances
- 550 pooled over samples S1-S3 in treated (T) and control (C) patients. Boxes highlight select taxa
- 551 discussed as modulating cancer immunotherapies<sup>31,32,35</sup>. \*\*\*: p<0.001, \*\*: p<0.01, \*: p<0.05, .:
- 552 p<0.1, n.s.: p>0.1; non-parametric Wilcoxon rank sums test not corrected for multiple
- 553 hypotheses.









#### **patients who received a postbiotic during their treatment and becomes similar ten days**

**after finishing the antibiotic.** Thick lines show a locally weighted scatterplot smoothing curve

for treated (purple) and control (grey) patients' bacterial alpha diversity across five

longitudinally collected samples; dashed lines and shaded regions show mean and confidence

intervals of a second-order line fit with time in days as predictor of alpha diversity.

#### **Bibliography**

- 1. Havey, T.C., Fowler, R.A., and Daneman, N. (2011). Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. Crit Care *15*, R267. 10.1186/cc10545.
- 2. Hutchings, M.I., Truman, A.W., and Wilkinson, B. (2019). Antibiotics: past, present and future. Curr Opin Microbiol *51*, 72–80. 10.1016/j.mib.2019.10.008.
- 3. Maier, L., Goemans, C.V., Wirbel, J., Kuhn, M., Eberl, C., Pruteanu, M., Müller, P., Garcia- Santamarina, S., Cacace, E., Zhang, B., et al. (2021). Unravelling the collateral damage of antibiotics on gut bacteria. Nature *599*, 120–124. 10.1038/s41586-021-03986-2.
- 4. Blaser, M.J. (2016). Antibiotic use and its consequences for the normal microbiome. Science *352*, 544–545. 10.1126/science.aad9358.
- 5. Modi, S.R., Collins, J.J., and Relman, D.A. (2014). Antibiotics and the gut microbiota. J Clin Invest *124*, 4212–4218. 10.1172/JCI72333.
- 6. Whangbo, J., Ritz, J., and Bhatt, A. (2017). Antibiotic-mediated modification of the intestinal microbiome in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant *52*, 183–190. 10.1038/bmt.2016.206.
- 7. Dethlefsen, L., and Relman, D.A. (2011). Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA *108 Suppl 1*, 4554–4561. 10.1073/pnas.1000087107.
- 8. Niehus, R., van Kleef, E., Mo, Y., Turlej-Rogacka, A., Lammens, C., Carmeli, Y., Goossens, H., Tacconelli, E., Carevic, B., Preotescu, L., et al. (2020). Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance. Elife *9*, e49206. 10.7554/eLife.49206.
- 9. Morjaria, S., Schluter, J., Taylor, B.P., Littmann, E.R., Carter, R.A., Fontana, E., Peled, J.U., van den Brink, M.R.M., Xavier, J.B., and Taur, Y. (2019). Antibiotic-Induced Shifts in Fecal Microbiota Density and Composition during Hematopoietic Stem Cell Transplantation. Infect Immun *87*. 10.1128/IAI.00206-19.
- 10. Bernard-Raichon, L., Venzon, M., Klein, J., Axelrad, J.E., Zhang, C., Sullivan, A.P., Hussey, G.A., Casanovas-Massana, A., Noval, M.G., Valero-Jimenez, A.M., et al. (2022). Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia. Nat Commun *13*, 5926. 10.1038/s41467-022-33395-6.
- 11. Schluter, J., Djukovic, A., Taylor, B.P., Yan, J., Duan, C., Hussey, G.A., Liao, C., Sharma, S., Fontana, E., Amoretti, L.A., et al. (2023). The TaxUMAP atlas: Efficient display of large clinical microbiome data reveals ecological competition in protection against bacteremia. Cell Host & Microbe. 10.1016/j.chom.2023.05.027.
- 12. Palleja, A., Mikkelsen, K.H., Forslund, S.K., Kashani, A., Allin, K.H., Nielsen, T., Hansen, T.H., Liang, S., Feng, Q., Zhang, C., et al. (2018). Recovery of gut microbiota of healthy

- adults following antibiotic exposure. Nat Microbiol *3*, 1255–1265. 10.1038/s41564-018- 0257-9.
- 13. Brandt, L.J., Aroniadis, O.C., Mellow, M., Kanatzar, A., Kelly, C., Park, T., Stollman, N., Rohlke, F., and Surawicz, C. (2012). Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol *107*, 1079–1087. 10.1038/ajg.2012.60.
- 14. Buffie, C.G., Bucci, V., Stein, R.R., McKenney, P.T., Ling, L., Gobourne, A., No, D., Liu, H., Kinnebrew, M., Viale, A., et al. (2015). Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature *517*, 205–208. 10.1038/nature13828.
- 15. Zhai, B., Ola, M., Rolling, T., Tosini, N.L., Joshowitz, S., Littmann, E.R., Amoretti, L.A., Fontana, E., Wright, R.J., Miranda, E., et al. (2020). High-resolution mycobiota analysis reveals dynamic intestinal translocation preceding invasive candidiasis. Nat Med *26*, 59–64. 10.1038/s41591-019-0709-7.
- 16. Willis, A.D. (2019). Rarefaction, Alpha Diversity, and Statistics. Front Microbiol *10*, 2407. 10.3389/fmicb.2019.02407.
- 17. Kers, J.G., and Saccenti, E. (2021). The power of microbiome studies: some considerations on which alpha and beta metrics to use and how to report results. Front Microbiol *12*, 796025. 10.3389/fmicb.2021.796025.
- 18. Peled, J.U., Gomes, A.L.C., Devlin, S.M., Littmann, E.R., Taur, Y., Sung, A.D., Weber, D., Hashimoto, D., Slingerland, A.E., Slingerland, J.B., et al. (2020). Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med *382*, 822–834. 10.1056/NEJMoa1900623.
- 19. Taur, Y., Jenq, R.R., Perales, M.-A., Littmann, E.R., Morjaria, S., Ling, L., No, D., Gobourne, A., Viale, A., Dahi, P.B., et al. (2014). The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood *124*, 1174–1182. 10.1182/blood-2014-02-554725.
- 20.Galloway-Peña, J.R., Smith, D.P., Sahasrabhojane, P., Ajami, N.J., Wadsworth, W.D., Daver, N.G., Chemaly, R.F., Marsh, L., Ghantoji, S.S., Pemmaraju, N., et al. (2016). The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer *122*, 2186–2196. 10.1002/cncr.30039.
- 21. Taur, Y., Xavier, J.B., Lipuma, L., Ubeda, C., Goldberg, J., Gobourne, A., Lee, Y.J., Dubin, K.A., Socci, N.D., Viale, A., et al. (2012). Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis *55*, 905–914. 10.1093/cid/cis580.
- 22. Faye, A.S., Allin, K.H., Iversen, A.T., Agrawal, M., Faith, J., Colombel, J.-F., and Jess, T. (2023). Antibiotic use as a risk factor for inflammatory bowel disease across the ages: a population-based cohort study. Gut *72*, 663–670. 10.1136/gutjnl-2022-327845.

 23.Wang, Q., Zhang, S.-X., Chang, M.-J., Qiao, J., Wang, C.-H., Li, X.-F., Yu, Q., and He, P.-F. (2022). Characteristics of the Gut Microbiome and Its Relationship With Peripheral CD4+ T Cell Subpopulations and Cytokines in Rheumatoid Arthritis. Front Microbiol *13*, 799602. 10.3389/fmicb.2022.799602.

- 24. Björkstén, B., Sepp, E., Julge, K., Voor, T., and Mikelsaar, M. (2001). Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol *108*, 516– 520. 10.1067/mai.2001.118130.
- 25. Azad, M.B., Bridgman, S.L., Becker, A.B., and Kozyrskyj, A.L. (2014). Infant antibiotic exposure and the development of childhood overweight and central adiposity. Int J Obes (Lond) *38*, 1290–1298. 10.1038/ijo.2014.119.
- 26. Clemente, J.C., Manasson, J., and Scher, J.U. (2018). The role of the gut microbiome in systemic inflammatory disease. BMJ *360*, j5145. 10.1136/bmj.j5145.

 27. Sultan, A.A., Mallen, C., Muller, S., Hider, S., Scott, I., Helliwell, T., and Hall, L.J. (2019). Antibiotic use and the risk of rheumatoid arthritis: a population-based case-control study. BMC Medicine *17*, 154. 10.1186/s12916-019-1394-6.

 28. Rao, C., Coyte, K.Z., Bainter, W., Geha, R.S., Martin, C.R., and Rakoff-Nahoum, S. (2021). Multi-kingdom ecological drivers of microbiota assembly in preterm infants. Nature *591*, 633–638. 10.1038/s41586-021-03241-8.

- 29. Tomczak, H., Szałek, E., and Grześkowiak, E. (2014). The problems of urinary tract infections with Candida spp. aetiology in women. Postepy Hig Med Dosw (Online) *68*, 1036–1039. 10.5604/17322693.1118989.
- 30. Smith, M., Dai, A., Ghilardi, G., Amelsberg, K.V., Devlin, S.M., Pajarillo, R., Slingerland, J.B., Beghi, S., Herrera, P.S., Giardina, P., et al. (2022). Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med *28*, 713–723. 10.1038/s41591-022-01702-9.
- 31. Gopalakrishnan, V., Spencer, C.N., Nezi, L., Reuben, A., Andrews, M.C., Karpinets, T.V., Prieto, P.A., Vicente, D., Hoffman, K., Wei, S.C., et al. (2018). Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science *359*, 97–103. 10.1126/science.aan4236.
- 32. Routy, B., Le Chatelier, E., Derosa, L., Duong, C.P.M., Alou, M.T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M.P., et al. (2018). Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science *359*, 91–97. 10.1126/science.aan3706.
- 33. Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J.J., and Gajewski, T.F. (2018). The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science *359*, 104–108. 10.1126/science.aao3290.

- 34. Hu, Y., Li, J., Ni, F., Yang, Z., Gui, X., Bao, Z., Zhao, H., Wei, G., Wang, Y., Zhang, M., et al. (2022). CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies. Nat Commun *13*, 5313. 10.1038/s41467-022-32960-3.
- 35. Schluter, J., Peled, J.U., Taylor, B.P., Markey, K.A., Smith, M., Taur, Y., Niehus, R., Staffas, A., Dai, A., Fontana, E., et al. (2020). The gut microbiota is associated with immune cell dynamics in humans. Nature *588*, 303–307. 10.1038/s41586-020-2971-8.
- 36. Olin, A., Henckel, E., Chen, Y., Lakshmikanth, T., Pou, C., Mikes, J., Gustafsson, A., Bernhardsson, A.K., Zhang, C., Bohlin, K., et al. (2018). Stereotypic immune system development in newborn children. Cell *174*, 1277-1292.e14. 10.1016/j.cell.2018.06.045.
- 37. Wastyk, H.C., Fragiadakis, G.K., Perelman, D., Dahan, D., Merrill, B.D., Yu, F.B., Topf, M., Gonzalez, C.G., Van Treuren, W., Han, S., et al. (2021). Gut-microbiota-targeted diets modulate human immune status. Cell *184*, 4137-4153 e14. 10.1016/j.cell.2021.06.019.
- 38. Taur, Y., Coyte, K., Schluter, J., Robilotti, E., Figueroa, C., Gjonbalaj, M., Littmann, E.R., Ling, L., Miller, L., Gyaltshen, Y., et al. (2018). Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Sci Transl Med *10*. 10.1126/scitranslmed.aap9489.
- 39. Costello, S.P., Hughes, P.A., Waters, O., Bryant, R.V., Vincent, A.D., Blatchford, P., Katsikeros, R., Makanyanga, J., Campaniello, M.A., Mavrangelos, C., et al. (2019). Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis. JAMA *321*, 156–164. 10.1001/jama.2018.20046.
- 40. Davar, D., Dzutsev, A.K., McCulloch, J.A., Rodrigues, R.R., Chauvin, J.-M., Morrison, R.M., Deblasio, R.N., Menna, C., Ding, Q., Pagliano, O., et al. (2021). Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science *371*, 595–602. 10.1126/science.abf3363.
- 41. Bakken, J.S., Polgreen, P.M., Beekmann, S.E., Riedo, F.X., and Streit, J.A. (2013). Treatment approaches including fecal microbiota transplantation for recurrent Clostridium difficile infection (RCDI) among infectious disease physicians. Anaerobe *24*, 20–24. 10.1016/j.anaerobe.2013.08.007.
- 42. van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E.G., de Vos, W.M., Visser, C.E., Kuijper, E.J., Bartelsman, J.F.W.M., Tijssen, J.G.P., et al. (2013). Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med *368*, 407–415. 10.1056/NEJMoa1205037.
- 43. Sandhu, A., and Chopra, T. (2021). Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls. Therap Adv Gastroenterol *14*, 17562848211053105. 10.1177/17562848211053105.
- 44. DeFilipp, Z., Bloom, P.P., Torres Soto, M., Mansour, M.K., Sater, M.R.A., Huntley, M.H., Turbett, S., Chung, R.T., Chen, Y.-B., and Hohmann, E.L. (2019). Drug-Resistant E. coli

 Bacteremia Transmitted by Fecal Microbiota Transplant. N Engl J Med *381*, 2043–2050. 10.1056/NEJMoa1910437.

- 45. Ianiro, G., Punčochář, M., Karcher, N., Porcari, S., Armanini, F., Asnicar, F., Beghini, F., Blanco-Míguez, A., Cumbo, F., Manghi, P., et al. (2022). Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases. Nat Med *28*, 1913–1923. 10.1038/s41591-022-01964-3.
- 46. Commissioner, O. of the (2022). FDA Approves First Fecal Microbiota Product. FDA. https://www.fda.gov/news-events/press-announcements/fda-approves-first-fecal-microbiota-product.
- 47. Commissioner, O. of the (2023). FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection. FDA. https://www.fda.gov/news-events/press-announcements/fda-approves-first-orally-administered-fecal-microbiota-product-prevention-recurrence-clostridioides.
- 48. Suez, J., Zmora, N., Segal, E., and Elinav, E. (2019). The pros, cons, and many unknowns of probiotics. Nat Med *25*, 716–729. 10.1038/s41591-019-0439-x.
- 49. Besselink, M.G., Santvoort, H.C. van, Buskens, E., Boermeester, M.A., Goor, H. van, Timmerman, H.M., Nieuwenhuijs, V.B., Bollen, T.L., Ramshorst, B. van, Witteman, B.J., et al. (2008). Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. The Lancet *371*, 651–659. 10.1016/S0140- 6736(08)60207-X.
- 50. Zmora, N., Zilberman-Schapira, G., Suez, J., Mor, U., Dori-Bachash, M., Bashiardes, S., Kotler, E., Zur, M., Regev-Lehavi, D., Brik, R.B.-Z., et al. (2018). Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features. Cell *174*, 1388-1405.e21. 10.1016/j.cell.2018.08.041.
- 51. Zhang, C., Derrien, M., Levenez, F., Brazeilles, R., Ballal, S.A., Kim, J., Degivry, M.-C., Quéré, G., Garault, P., van Hylckama Vlieg, J.E.T., et al. (2016). Ecological robustness of the gut microbiota in response to ingestion of transient food-borne microbes. ISME J *10*, 2235–2245. 10.1038/ismej.2016.13.
- 52. Salminen, M.K., Rautelin, H., Tynkkynen, S., Poussa, T., Saxelin, M., Valtonen, V., and Järvinen, A. (2004). Lactobacillus Bacteremia, Clinical Significance, and Patient Outcome, with Special Focus on Probiotic L. Rhamnosus GG. Clin Infect Dis *38*, 62–69. 10.1086/380455.
- 53. Cassone, M., Serra, P., Mondello, F., Girolamo, A., Scafetti, S., Pistella, E., and Venditti, M. (2003). Outbreak of Saccharomyces cerevisiae Subtype boulardii Fungemia in Patients Neighboring Those Treated with a Probiotic Preparation of the Organism. Journal of Clinical Microbiology. 10.1128/jcm.41.11.5340-5343.2003.
- 54.Suez, J., Zmora, N., Zilberman-Schapira, G., Mor, U., Dori-Bachash, M., Bashiardes, S., Zur, M., Regev-Lehavi, D., Brik, R.B.-Z., Federici, S., et al. (2018). Post-Antibiotic Gut Mucosal

- Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT. Cell *174*, 1406-1423.e16. 10.1016/j.cell.2018.08.047.
- 55. Salminen, S., Collado, M.C., Endo, A., Hill, C., Lebeer, S., Quigley, E.M.M., Sanders, M.E., Shamir, R., Swann, J.R., Szajewska, H., et al. (2021). The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol *18*, 649–667. 10.1038/s41575-021- 00440-6.
- 56. Zhou, X., Qi, W., Hong, T., Xiong, T., Gong, D., Xie, M., and Nie, S. (2018). Exopolysaccharides from Lactobacillus plantarum NCU116 Regulate Intestinal Barrier Function via STAT3 Signaling Pathway. J Agric Food Chem *66*, 9719–9727. 10.1021/acs.jafc.8b03340.
- 57.Mosca, A., Abreu Y Abreu, A.T., Gwee, K.A., Ianiro, G., Tack, J., Nguyen, T.V.H., and Hill, C. (2022). The clinical evidence for postbiotics as microbial therapeutics. Gut Microbes *14*, 2117508. 10.1080/19490976.2022.2117508.
- 58. Stein-Thoeringer, C.K., Saini, N.Y., Zamir, E., Blumenberg, V., Schubert, M.-L., Mor, U., Fante, M.A., Schmidt, S., Hayase, E., Hayase, T., et al. (2023). A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med *29*, 906–916. 10.1038/s41591-023-02234-6.
- 59. Schulz, K.F., Altman, D.G., Moher, D., and CONSORT Group (2010). CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ *340*, c332. 10.1136/bmj.c332.
- 60. Barbut, F., and Meynard, J.L. (2002). Managing antibiotic associated diarrhoea. BMJ *324*, 1345–1346.
- 61. Hensgens, M.P.M., Goorhuis, A., Dekkers, O.M., and Kuijper, E.J. (2012). Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother *67*, 742–748. 10.1093/jac/dkr508.
- 62. Wilton, L., Kollarova, M., Heeley, E., and Shakir, S. (2003). Relative risk of vaginal candidiasis after use of antibiotics compared with antidepressants in women: postmarketing surveillance data in England. Drug Saf *26*, 589–597. 10.2165/00002018-200326080-00005.
- 63. Yu, D., Du, J., Pu, X., Zheng, L., Chen, S., Wang, N., Li, J., Chen, S., Pan, S., and Shen, B. (2022). The Gut Microbiome and Metabolites Are Altered and Interrelated in Patients With Rheumatoid Arthritis. Front Cell Infect Microbiol *11*, 763507. 10.3389/fcimb.2021.763507.
- 64. Nie, K., Ma, K., Luo, W., Shen, Z., Yang, Z., Xiao, M., Tong, T., Yang, Y., and Wang, X. (2021). Roseburia intestinalis: A Beneficial Gut Organism From the Discoveries in Genus and Species. Front Cell Infect Microbiol *11*, 757718. 10.3389/fcimb.2021.757718.
- 65. Bui, T.P.N., Mannerås-Holm, L., Puschmann, R., Wu, H., Troise, A.D., Nijsse, B., Boeren, S., Bäckhed, F., Fiedler, D., and deVos, W.M. (2021). Conversion of dietary inositol into

 propionate and acetate by commensal Anaerostipes associates with host health. Nat Commun *12*, 4798. 10.1038/s41467-021-25081-w.

- 66. Freier, T.A., Beitz, D.C., Li, L., and Hartman, P.A. (1994). Characterization of Eubacterium coprostanoligenes sp. nov., a cholesterol-reducing anaerobe. Int J Syst Bacteriol *44*, 137–142. 10.1099/00207713-44-1-137.
- 67. Mima, K., Sukawa, Y., Nishihara, R., Qian, Z.R., Yamauchi, M., Inamura, K., Kim, S.A., Masuda, A., Nowak, J.A., Nosho, K., et al. (2015). Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. JAMA Oncol *1*, 653–661. 10.1001/jamaoncol.2015.1377.
- 68. Brennan, C.A., and Garrett, W.S. (2019). Fusobacterium nucleatum symbiont, opportunist and oncobacterium. Nat Rev Microbiol *17*, 156–166. 10.1038/s41579-018-0129-6.
- 69. Osbelt, L., Wende, M., Almási, É., Derksen, E., Muthukumarasamy, U., Lesker, T.R., Galvez, E.J.C., Pils, M.C., Schalk, E., Chhatwal, P., et al. (2021). Klebsiella oxytoca causes colonization resistance against multidrug-resistant K. pneumoniae in the gut via cooperative carbohydrate competition. Cell Host Microbe. 10.1016/j.chom.2021.09.003.
- 70. Oliveira, R.A., Ng, K.M., Correia, M.B., Cabral, V., Shi, H., Sonnenburg, J.L., Huang, K.C., and Xavier, K.B. (2020). Klebsiella michiganensis transmission enhances resistance to Enterobacteriaceae gut invasion by nutrition competition. Nat Microbiol *5*, 630–641. 811 10.1038/s41564-019-0658-4.
- 71. Buffie, C.G., and Pamer, E.G. (2013). Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol *13*, 790–801. 10.1038/nri3535.
- 72. Roswall, J., Olsson, L.M., Kovatcheva-Datchary, P., Nilsson, S., Tremaroli, V., Simon, M.- C., Kiilerich, P., Akrami, R., Krämer, M., Uhlén, M., et al. (2021). Developmental trajectory of the healthy human gut microbiota during the first 5 years of life. Cell Host & Microbe *29*, 765-776.e3. 10.1016/j.chom.2021.02.021.
- 73. Vatanen, T., Franzosa, E.A., Schwager, R., Tripathi, S., Arthur, T.D., Vehik, K., Lernmark, Å., Hagopian, W.A., Rewers, M.J., She, J.-X., et al. (2018). The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature *562*, 589–594. 10.1038/s41586- 018-0620-2.
- 74.Coyte, K.Z., Schluter, J., and Foster, K.R. (2015). The ecology of the microbiome: Networks, competition, and stability. Science *350*, 663–666. 10.1126/science.aad2602.
- 75. Button, J.E., Cosetta, C.M., Reens, A.L., Brooker, S.L., Rowan-Nash, A.D., Lavin, R.C., Saur, R., Zheng, S., Autran, C.A., Lee, M.L., et al. (2023). Precision modulation of dysbiotic adult microbiomes with a human-milk-derived synbiotic reshapes gut microbial composition and metabolites. Cell Host & Microbe. 10.1016/j.chom.2023.08.004.
- 76. Seabold, S., and Perktold, J. (2010). Statsmodels: Econometric and Statistical Modeling with 829 Python. Proceedings of the 9th Python in Science Conference, 92–96. 10.25080/Majora-92bf1922-011.

- 77. Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O., Blondel, M., Prettenhofer, P., Weiss, R., Dubourg, V., et al. (2011). Scikit-learn: Machine Learning in Python. Journal of Machine Learning Research *12*, 2825–2830.
- 78. Pinheiro, J.C., Bates, D.M., DebRoy, S.S., and Sarkar, D. (2013). Nlme: Linear and Nonlinear Mixed Effects Models.
- 79. Oksanen, J., Simpson, G.L., Blanchet, F.G., Kindt, R., Legendre, P., Minchin, P.R., O'Hara, R.B., Solymos, P., Stevens, M.H.H., Szoecs, E., et al. (2022). vegan: Community Ecology Package.





